舒尼替尼治疗晚期肾癌的疗效及不良反应单中心分析  

Single center analysis of the efficacy and side-effect of sunitinib treatment for patients with advanced renal carcinoma

作　　者：马晓诚[1] 宋吉叶 施彩凤[3] 张桂铭[1] 李斌[1] 孙立江[1] 骆磊[1] MA Xiaocheng;SONG Jiye;SHI Caifeng;ZHANG Guiming;LI Bin;SUN Lijiang;LUO Lei(Department of Urology, Affiliated Hospital of Qingdao University, Qingdao 266001, China)

机构地区：[1]青岛大学附属医院泌尿外科,266001 [2]青岛大学附属医院儿童医学中心 [3]青岛大学附属医院麻醉科

出　　处：《现代泌尿生殖肿瘤杂志》2019年第1期11-13,共3页Journal of Contemporary Urologic and Reproductive Oncology

基　　金：国家自然科学基金(81502195;81672512);山东省医药卫生科技发展计划(2016WS0258)

摘　　要：目的分析舒尼替尼对于晚期肾癌患者的疗效及不良反应。方法 2012年9月至2016年1月于青岛大学附属医院泌尿外科接受舒尼替尼治疗的31例晚期肾癌患者纳入研究,其中单发转移灶24例、多发转移灶7例。接受舒尼替尼50mg 4/2方案28例,37.5mg持续给药方案1例,50mg 2/1方案2例。总结分析其疗效和不良反应等。结果完全缓解4例(12.9%)、部分缓解2例(6.5%)、疾病平稳15例(48.4%)、疾病进展10例(32.3%),疾病控制率67.7%。主要不良反应有手足综合征(90.3%)、乏力(87.1%)和味觉减退(77.4%)等。轻度不良反应率80.6%。结论舒尼替尼治疗晚期肾癌可获得较高的疾病控制率,不良反应多数较轻且易耐受。Objective To analyse the efficacy and side-effect of sunitinib in the treatment of advanced renal carcinoma in a single center. MethodsA retrospective analysis was made for metastatic renal cell carcinoma (mRCC) patients treated with sunitinib from Sep.2012 to Jan.2016 in Affiliated Hospital of Qingdao University. Twenty-eight patients received sunitinib 50 mg Qd, 4/2 weeks schedule primarily, 2 patients received 50 mg Qd, 2/1 weeks schedule and 1 patient received 37.5 mg Qd. ResultsTwenty-six male and 5 female patients were analyzed. Four cases were CR (12.9%), 2 cases were PR(6.5%), 15 cases were SD (48.4%) and 10 cases were PD (32.3%). Disease control rate was 67.7%. The main side-effect included hand-foot syndrome (90.3%), fatigue (87.1%), hypogeusia(77.4%), etc. Side-effect of 1-2 grade was found in 80.6% patients. ConclusionsAs the first-line therapy for patients with mRCC, sunitinib can gain high disease control rate and slight-to-mild side-effect, which is safe and well tolerated.

关 键 词：舒尼替尼 肾癌 疗效 不良反应 

分 类 号：R737.11[医药卫生—肿瘤]